Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alzheimer's disease drug

Executive Summary

Sen. Pell (D-R.I.) introduced legislation to require the National Institute on Aging to provide $2 mil. per year for a three-year study of tacrine (tetrahydroaminoacridine or THA) for treatment of senile dementia. Warner-Lambert has expressed interest in developing the cholinergic agent, which was first marketed in the 1930s. The Senate Labor & Human Resources Committee member noted that tacrine achieved a 92% success rate in a private study conducted in 19 patients and published last fall in the New England Journal of Medicine.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS011853

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel